Table of Contents

1 Study Coverage

• 1.1 Medical Asparaginase Product
• 1.2 Market Segments
• 1.3 Key Manufacturers Covered
• 1.4 Market by Type
  • 1.4.1 Global Medical Asparaginase Market Size Growth Rate by Product
  • 1.4.2 Escherichia coli
  • 1.4.3 Erwinia Chrysanthemi
  • 1.4.4 Pegylated
• 1.5 Market by End User
  • 1.5.1 Global Medical Asparaginase Market Size Growth Rate by End User
  • 1.5.2 Acute Lymphoblastic Leukemia
  • 1.5.3 Acute Myeloid Leukemia
  • 1.5.4 Other
• 1.6 Study Objectives
• 1.7 Years Considered

2 Executive Summary

• 2.1 Global Medical Asparaginase Market Size
  • 2.1.1 Global Medical Asparaginase Revenue 2014-2025
  • 2.1.2 Global Medical Asparaginase Sales 2014-2025
• 2.2 Medical Asparaginase Growth Rate by Regions
  • 2.2.1 Global Medical Asparaginase Sales by Regions
  • 2.2.2 Global Medical Asparaginase Revenue by Regions

3 Breakdown Data by Manufacturers

• 3.1 Medical Asparaginase Sales by Manufacturers
  • 3.1.1 Medical Asparaginase Sales by Manufacturers
  • 3.1.2 Medical Asparaginase Sales Market Share by Manufacturers
  • 3.1.3 Global Medical Asparaginase Market Concentration Ratio (CR5 and HHI)
• 3.2 Medical Asparaginase Revenue by Manufacturers
  • 3.2.1 Medical Asparaginase Revenue by Manufacturers (2014-2019)
  • 3.2.2 Medical Asparaginase Revenue Share by Manufacturers (2014-2019)
• 3.3 Medical Asparaginase Price by Manufacturers
• 3.4 Medical Asparaginase Manufacturing Base Distribution, Product Types
  • 3.4.1 Medical Asparaginase Manufacturers Manufacturing Base Distribution, Headquarters
  • 3.4.2 Manufacturers Medical Asparaginase Product Type
  • 3.4.3 Date of International Manufacturers Enter into Medical Asparaginase Market
• 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product

• 4.1 Global Medical Asparaginase Sales by Product
• 4.2 Global Medical Asparaginase Revenue by Product
• 4.3 Medical Asparaginase Price by Product

5 Breakdown Data by End User

• 5.1 Overview
• 5.2 Global Medical Asparaginase Breakdown Data by End User

6 North America

• 6.1 North America Medical Asparaginase by Countries
  • 6.1.1 North America Medical Asparaginase Sales by Countries
  • 6.1.2 North America Medical Asparaginase Revenue by Countries
  • 6.1.3 United States
  • 6.1.4 Canada
  • 6.1.5 Mexico
• 6.2 North America Medical Asparaginase by Product
• 6.3 North America Medical Asparaginase by End User

7 Europe

• 7.1 Europe Medical Asparaginase by Countries
  • 7.1.1 Europe Medical Asparaginase Sales by Countries
  • 7.1.2 Europe Medical Asparaginase Revenue by Countries
  • 7.1.3 Germany
  • 7.1.4 France
  • 7.1.5 UK
  • 7.1.6 Italy
  • 7.1.7 Russia
• 7.2 Europe Medical Asparaginase by Product
• 7.3 Europe Medical Asparaginase by End User

8 Asia Pacific

• 8.1 Asia Pacific Medical Asparaginase by Countries
  • 8.1.1 Asia Pacific Medical Asparaginase Sales by Countries
  • 8.1.2 Asia Pacific Medical Asparaginase Revenue by Countries
  • 8.1.3 China
  • 8.1.4 Japan
  • 8.1.5 Korea
  • 8.1.6 India
  • 8.1.7 Australia
  • 8.1.8 Indonesia
  • 8.1.9 Malaysia
  • 8.1.10 Philippines
  • 8.1.11 Thailand
  • 8.1.12 Vietnam
  • 8.1.13 Singapore
• 8.2 Asia Pacific Medical Asparaginase by Product
• 8.3 Asia Pacific Medical Asparaginase by End User

9 Central & South America

• 9.1 Central & South America Medical Asparaginase by Countries
  • 9.1.1 Central & South America Medical Asparaginase Sales by Countries
  • 9.1.2 Central & South America Medical Asparaginase Revenue by Countries
  • 9.1.3 Brazil
• 9.2 Central & South America Medical Asparaginase by Product
• 9.3 Central & South America Medical Asparaginase by End User

10 Middle East and Africa

• 10.1 Middle East and Africa Medical Asparaginase by Countries
  • 10.1.1 Middle East and Africa Medical Asparaginase Sales by Countries
  • 10.1.2 Middle East and Africa Medical Asparaginase Revenue by Countries
  • 10.1.3 GCC Countries
  • 10.1.4 Turkey
  • 10.1.5 Egypt
  • 10.1.6 South Africa
• 10.2 Middle East and Africa Medical Asparaginase by Product
• 10.3 Middle East and Africa Medical Asparaginase by End User

11 Company Profiles

• 11.1 Jazz Pharmaceuticals
  • 11.1.1 Jazz Pharmaceuticals Company Details
  • 11.1.2 Company Business Overview
  • 11.1.3 Jazz Pharmaceuticals Medical Asparaginase Sales, Revenue and Gross Margin (2014-2019)
  • 11.1.4 Jazz Pharmaceuticals Medical Asparaginase Products Offered
  • 11.1.5 Jazz Pharmaceuticals Recent Development
• 11.2 Shire
  • 11.2.1 Shire Company Details
  • 11.2.2 Company Business Overview
  • 11.2.3 Shire Medical Asparaginase Sales, Revenue and Gross Margin (2014-2019)
  • 11.2.4 Shire Medical Asparaginase Products Offered
  • 11.2.5 Shire Recent Development
• 11.3 Medac GmbH
  • 11.3.1 Medac GmbH Company Details
  • 11.3.2 Company Business Overview
  • 11.3.3 Medac GmbH Medical Asparaginase Sales, Revenue and Gross Margin (2014-2019)
  • 11.3.4 Medac GmbH Medical Asparaginase Products Offered
  • 11.3.5 Medac GmbH Recent Development
• 11.4 Kyowa Hakko Kirin
  • 11.4.1 Kyowa Hakko Kirin Company Details
  • 11.4.2 Company Business Overview
  • 11.4.3 Kyowa Hakko Kirin Medical Asparaginase Sales, Revenue and Gross Margin (2014-2019)
  • 11.4.4 Kyowa Hakko Kirin Medical Asparaginase Products Offered
  • 11.4.5 Kyowa Hakko Kirin Recent Development
• 11.5 Qianhong Bio-pharma
  • 11.5.1 Qianhong Bio-pharma Company Details
  • 11.5.2 Company Business Overview
  • 11.5.3 Qianhong Bio-pharma Medical Asparaginase Sales, Revenue and Gross Margin (2014-2019)
  • 11.5.4 Qianhong Bio-pharma Medical Asparaginase Products Offered
  • 11.5.5 Qianhong Bio-pharma Recent Development
• 11.6 Taj Pharmaceuticals
  • 11.6.1 Taj Pharmaceuticals Company Details
  • 11.6.2 Company Business Overview
  • 11.6.3 Taj Pharmaceuticals Medical Asparaginase Sales, Revenue and Gross Margin (2014-2019)
  • 11.6.4 Taj Pharmaceuticals Medical Asparaginase Products Offered
  • 11.6.5 Taj Pharmaceuticals Recent Development
• 11.7 Mingxing Pharma
  • 11.7.1 Mingxing Pharma Company Details
  • 11.7.2 Company Business Overview
  • 11.7.3 Mingxing Pharma Medical Asparaginase Sales, Revenue and Gross Margin (2014-2019)
  • 11.7.4 Mingxing Pharma Medical Asparaginase Products Offered
  • 11.7.5 Mingxing Pharma Recent Development
• 11.8 SL Pharma
  • 11.8.1 SL Pharma Company Details
  • 11.8.2 Company Business Overview
  • 11.8.3 SL Pharma Medical Asparaginase Sales, Revenue and Gross Margin (2014-2019)
  • 11.8.4 SL Pharma Medical Asparaginase Products Offered
  • 11.8.5 SL Pharma Recent Development
• 11.9 United Biotech
  • 11.9.1 United Biotech Company Details
  • 11.9.2 Company Business Overview
  • 11.9.3 United Biotech Medical Asparaginase Sales, Revenue and Gross Margin (2014-2019)
  • 11.9.4 United Biotech Medical Asparaginase Products Offered
  • 11.9.5 United Biotech Recent Development

12 Future Forecast

• 12.1 Medical Asparaginase Market Forecast by Regions
  • 12.1.1 Global Medical Asparaginase Sales Forecast by Regions 2019-2025
  • 12.1.2 Global Medical Asparaginase Revenue Forecast by Regions 2019-2025
• 12.2 Medical Asparaginase Market Forecast by Product
  • 12.2.1 Global Medical Asparaginase Sales Forecast by Product 2019-2025
  • 12.2.2 Global Medical Asparaginase Revenue Forecast by Product 2019-2025
• 12.3 Medical Asparaginase Market Forecast by End User
• 12.4 North America Medical Asparaginase Forecast
• 12.5 Europe Medical Asparaginase Forecast
• 12.6 Asia Pacific Medical Asparaginase Forecast
• 12.7 Central & South America Medical Asparaginase Forecast
• 12.8 Middle East and Africa Medical Asparaginase Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

• 13.1 Market Opportunities and Drivers
• 13.2 Market Challenges
• 13.3 Market Risks/Restraints
• 13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis

• 14.1 Value Chain Analysis
• 14.2 Medical Asparaginase Customers
• 14.3 Sales Channels Analysis
  • 14.3.1 Sales Channels
  • 14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix

• 16.1 Research Methodology
  • 16.1.1 Methodology/Research Approach
  • 16.1.2 Data Source
• 16.2 Author Details

Asparaginase is an enzyme, as a medication it is used to treat acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and non-Hodgkin's lymphoma. It is given by injection into a vein, muscle, or under the skin. A pegylated version is also available.
Asparaginase was approved for medical use in the United States in 1978. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system.

The classification of Medical Asparaginase includes Escherichia coli, Erwinia Chrysanthemi and Pegylated, and the sales proportion of Escherichia coli in 2017 is about 64.6%, and the proportion is decreasing trend from 2013 to 2018.

Medical Asparaginase is widely sales for Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia and Others. The most proportion of Medical Asparaginase is sales in Acute Lymphoblastic Leukemia, and the consumption proportion is about 90% in 2017.

North America is the largest consumption place, with a revenue market share nearly 53.5% in 2017. Following North America, Europe is the second largest consumption place with the revenue market share of 37.2%, China is also an important sales region for the Medical Asparaginase, In China, the price is lower than the developed countries.

Market competition is intense. Jazz Pharmaceuticals, Shire, Medac GmbH, Kyowa Hakko Kirin, etc. are the leaders of the industry. They hold the key technologies and patents, with high-end customers. They have formed global market channel of the industry. However, with the future expanding market, there will be more manufacturers in the future.

The global Medical Asparaginase market is valued at 390 million US$ in 2018 and will reach 440 million US$ by the end of 2025, growing at a CAGR of 1.4% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Medical Asparaginase market based on company, product type, end user and key regions.

This report studies the global market size of Medical Asparaginase in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Medical Asparaginase in these regions.
This research report categorizes the global Medical Asparaginase market by top players/brands, region, type and end user. This report also studies the global Medical Asparaginase market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Jazz Pharmaceuticals
Shire
Medac GmbH
Kyowa Hakko Kirin
Qianhong Bio-pharma
Taj Pharmaceuticals
Mingxing Pharma
SL Pharma
United Biotech

Market size by Product
Escherichia coli
Erwinia Chrysanthemi
Pegylated
Market size by End User
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Other

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Medical Asparaginase market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Medical Asparaginase market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Medical Asparaginase companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Medical Asparaginase submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Medical Asparaginase are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Medical Asparaginase market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.